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Human Collagen Krox Up-regulates Type I Collagen
Expression in Normal and Scleroderma Fibroblasts through
Interaction with Sp1 and Sp3 Transcription Factors*□
S
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Despite several investigations, the transcriptional mechanisms that regulate the expression of both type I collagen genes
(COL1A1 and COL1A2) in either physiological or pathological
situations, such as scleroderma, are not completely known. We
have investigated the role of hc-Krox transcription factor on
type I collagen expression by human dermal fibroblasts.
hc-Krox exerted a stimulating effect on type I collagen protein
synthesis and enhanced the corresponding mRNA steady-state
levels of COL1A1 and COL1A2 in foreskin fibroblasts (FF), adult
normal fibroblasts (ANF), and scleroderma fibroblasts (SF).
Forced hc-Krox expression was found to up-regulate COL1A1
transcription through a ⴚ112/ⴚ61-bp sequence in FF, ANF, and
SF. Knockdown of hc-Krox by short interfering RNA and decoy
strategies confirmed the transactivating effect of hc-Krox and
decreased substantially COL1A1 transcription levels in all fibroblast types. The ⴚ112/ⴚ61-bp sequence bound specifically hcKrox but also Sp1 and CBF. Attempts to elucidate the potential
interactions between hc-Krox, Sp1, and Sp3 revealed that all of
them co-immunoprecipitate from FF cellular extracts when a
c-Krox antibody was used and bind to the COL1A1 promoter in
chromatin immunoprecipitation assays. Moreover, hc-Krox
DNA binding activity to its COL1A1-responsive element is
increased in SF, cells producing higher amounts of type I collagen compared with ANF and FF. These data suggest that the
regulation of COL1A1 gene transcription in human dermal
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fibroblasts involves a complex machinery that implicates at least
three transcription proteins, hc-Krox, Sp1, and Sp3, which
could act in concert to up-regulate COL1A1 transcriptional
activity and provide evidence for a pro-fibrotic role of hc-Krox.

Fibroblasts represent the main cellular population of dermis.
Their principal function is to maintain the extracellular matrix
(ECM)5 homeostasis. A complex network of cytokines/growth
factors, acting by autocrine and paracrine mechanisms, controls the fibroblast metabolism and ensures the tissue integrity.
In a normal situation, there is a balance between synthesis and
degradation of the matrix components, including elastic fibers,
proteoglycans, and collagens (1, 2). This equilibrium is disrupted in pathological processes, such as fibrosis, and characterized by excessive production of matrix proteins, particularly
of type I collagen, which is the major structural component of
dermal ECM (2).
Type I collagen is composed of two ␣1 chains and one ␣2
chain, encoded by two distinct genes, COL1A1 and COL1A2,
respectively (3). Coordinated transcription of these genes
involves similar cis elements interacting with the same transcription factors, such as Sp1, Sp3, CBF (CCAAT-binding factor), and c-Krox (collagen-Krüppel box) (4 –15). The relative
proportions and/or interactions between these and other transcription factors are responsible for the modulation of type I
collagen expression under physiopathological conditions.
Human c-Krox (hc-Krox) is a zinc finger transcription factor
belonging to the Krox family proteins and binds to GC-rich
sequences. This protein harbors a BTB-POZ (for “broad complex, tramtrack, and bric à brac/pox virus and zinc finger”)
domain in its N-terminal extremity, which is responsible for
protein homo- and heterodimerization and for the inhibition of
5

The abbreviations used are: ECM, extracellular matrix; siRNA, short interfering RNA; RT, reverse transcription; EMSA, electrophoretic mobility shift
assay; FF, foreskin fibroblast; ANF, adult normal fibroblast; SF, scleroderma
fibroblast; CBF, CCAAT-binding factor; c-Krox, collagen-Krüppel box; hc,
human collagen; mc, mouse collagen.
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From the ‡Laboratoire de Biochimie du Tissu Conjonctif, Université de Caen/Basse-Normandie, IFR ICORE 146, Faculté de Médecine,
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through a ⫺112/⫺61-bp promoter sequence. The factor can
bind to this promoter region in vitro and in vivo, as well as Sp1
and CBF.
Our results reveal for the first time the transactivating role of
hc-Krox on human COL1A1 gene in normal and pathological
human dermal fibroblasts and provide evidence for interactions between hc-Krox, Sp1, and Sp3. Moreover, the data suggest that hc-Krox is a pro-fibrogenic factor, because its DNA
binding is increased in SF compared with ANF, and this is correlated with enhanced type I collagen expression, and this offers
new perspectives for therapeutic strategies that could be
applied to fibrotic diseases and aging-related skin disorders.

EXPERIMENTAL PROCEDURES
Cell Cultures—Children foreskin samples were provided by
Dr. P. Ravasse (Dept. of Children Surgery, Caen Hospital, Caen,
France). Human ANF and SF were obtained from forearm biopsies of either healthy donors or patients suffering from localized
scleroderma (Prof. F.-X. Maquart, Laboratory of Medical Biochemistry and Molecular Biology, Reims, France). Fibroblasts
were obtained after explant cultures and seeded at 2.5 ⫻ 106
cells/cm2 in 175-cm2 flasks, in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum, glutamine (2
mM), penicillin (100 IU/ml), streptomycin (100 g/ml), and
fungizone (0.25 g/ml) in a 5% CO2 environment. They were
passaged with a trypsin (0.05%), EDTA (0.25 mM) solution
(Invitrogen) after reaching confluency. All the experiments
were performed on cells between 5 and 9 passages.
Collagen Labeling and Assay—Fibroblasts were seeded at
0.17 ⫻ 105 cells/9.6-cm2 wells, in 10% fetal calf serum-containing Dulbecco’s modified Eagle’s medium, and transiently transfected, or not, by the calcium phosphate precipitation method
with the hc-Krox expression vector and/or the corresponding
insertless plasmid (pSG5/hc-Krox). After 15 h, the culture
medium was replaced by the same fresh medium supplemented
with ␤-aminopropionitrile (50 g/ml) and ascorbic acid (50
g/ml) for a further 24-h period. The same medium was then
renewed, and [3H]proline (2 Ci/ml) (PerkinElmer Life Sciences) was added. After 24 h, the culture medium was collected,
and the labeled collagen was assayed, using the bacterial collagenase method (37). The cell layer was scraped, and the extracts
were sonicated. They were used to assay cell protein levels,
using the Bradford colorimetric assay. Levels of collagen and
noncollagenous proteins were corrected for total protein
amount.
An alternative method of transfection was also used to estimate collagen neosynthesis in the siRNA knockdown experiments. Fibroblasts were trypsinized at confluency and then distributed in Eppendorf tubes (1 ⫻ 106 cells per 1.5-ml tube).
Cells were centrifuged for 10 min at 200 ⫻ g and transfected
using the Nucleofector apparatus (AMAXA, Köln, Germany),
according to the manufacturer’s instructions. After the transfection of hc-Krox siRNA (1 g), the cells were plated and incubated in the same media, and the bacterial collagenase assay was
performed as described above.
Site-directed Mutagenesis—Mutant collagen promoters were
made using the ⫺804hCOL-LUC as a template for PCR
together with mutated oligonucleotides as follows. A 30-mer
JOURNAL OF BIOLOGICAL CHEMISTRY
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transcriptional activity of ECM-targeted genes (16). hc-Krox
has already been found to inhibit type I collagen (COL1A1 and
COL1A2), fibronectin, and elastin genes in fibroblastic cells and
uridine diphosphoglucose dehydrogenase (UGDH) in rabbit
articular chondrocytes (17, 18).
On the other hand, the murine homologue of hc-Krox,
mouse c-Krox (mc-Krox), was first cloned as a partial cDNA
lacking the BTB-POZ domain and was demonstrated to be an
activator of transcription of mouse Col1a1 and Col1a2 genes in
fibroblastic cells (14). This transcription factor is expressed in a
quite specific manner in the dermis, although it is absent in
bone (14, 15). Its expression can be detected at 9.5 days postcoitum in the myodermatomes and it precedes type I collagen
expression. These data, reporting the co-localization of type I
collagen and c-Krox expression in skin fibroblasts, suggest the
possible involvement of the trans factor in the fibrotic process,
particularly in scleroderma. Further support to this hypothesis
comes from the fact that the full-length mc-Krox (containing
the BTB-POZ domain) was recently found to promote thymocyte differentiation into CD4⫹ T cells rather than into CD8⫹ T
cells (19, 20). Knowing that during the early stages of scleroderma disease there is an activation of CD4⫹ T cells, rather
than of CD8⫹ T cells (21), we may suppose that c-Krox plays an
important role in the early manifestation of this disease that
leads to fibrotic reaction in later stages.
Sp1 and Sp3 are ubiquitous proteins belonging to the family
of Sp transcription factors recognizing GC and TC boxes, like
c-Krox (22). Sp1 is a well characterized activator of type I collagen genes (6, 12, 23–25); however, its function seems to
depend on the cellular and/or molecular context. It has been
shown to inhibit mouse Col1a1 gene in NIH-3T3 fibroblasts
(26) and to function as a co-inhibitor of human COL1A2 gene
transcription when it interacts with the transcription factor
Fli-1 in human skin fibroblasts (27). Additionally, Sp1 may play
a role in fibrotic diseases, because it is one of the mediators of
transforming growth factor-␤1, a profibrogenic factor that activates human COL1A1 gene transcription (10, 22, 28). In this
regard, its binding activity is increased in human scleroderma
fibroblasts and in hepatic stellate cells, compared with normal
cells (23, 29).
Sp3 shares identical binding sites and affinities with Sp1.
Consequently, it often behaves like an Sp1 antagonist in many
systems, competing with the latter for the same DNA sites,
reducing Sp1 binding activity, and inducing inhibition of gene
transcription (30 –33). Moreover, Sp3 on its own exerts bifunctional effects on gene transcription. These effects can be celland/or promoter-specific, but it can also depend on the number
of binding sites available for Sp3 on a given gene (34 –35).
Recent findings show that there exist four Sp3 isoforms, resulting from alternative translational start sites. Thus, Sp3 does not
appear as a simple Sp1 homologue but is rather controlled by
complex mechanisms of expression (36).
In this study, we investigated the functions of hc-Krox in
human dermal fibroblasts. We found that hc-Krox increases
type I collagen synthesis in human foreskin fibroblasts (FF)
obtained from young children, adult normal fibroblasts (ANF),
and scleroderma fibroblasts (SF). Moreover, hc-Krox enhances
human COL1A1 transcriptional activity in FF, ANF, and SF

hc-Krox Role in Human Dermal Fibroblasts
TABLE 1
Primers used in real time RT-PCR experiments (Eurogentec)
Gene of interest

Forward primer (orientation 5ⴕ 3 3ⴕ)

Reverse primer (orientation 5ⴕ 3 3ⴕ)

COL1A1
COL1A2
hc-Krox
COL3A1
ARNr 18 S

CACCAATCACCTGCGGTACAGAA
AAAACATCCCAGCCAAGAACTG
AGGGTTCTGGAAGATGAAATGAGT
TCTTGGTCAGTCCTATGCGGATA
CGGCTACCACATCCAAGGAA

CAGATCACGTCATCGCACAAC
AAACTGGCTGCCAGCATTG
AAGAGGACCAACTTTAGCCAATACTT
CATCGCAGAGAACGGATCCT
GCTGGAATTACCGCGGCT
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TABLE 2
Oligonucleotides used in this study (Eurogentec)
Oligonucleotide
name

Sequence (potential binding sites for
CBF, Sp1/Sp3, and c-Krox transcription
factors are in boldface)

SOX9 (“decoy” control) 5⬘-AGCCCCATTCATGAGAGACGAGGT-3⬘
⫺112/⫺61 wild type
5⬘-AGGCAGCTCTGATTGGCTGGGGCACGGGCGG
CCGGCTCCCCCTCTCCGAGGG-3⬘
5⬘-CTTGCGGGAGGGGGGGCGCTGGGTGGACA-3⬘
A␣1(I) wild type

after Nucleofector transfection, and 17 h after transfection
by the calcium phosphate precipitation procedure, the
medium was replaced by fresh medium. 6 h (nucleofection
procedure) or 24 h (calcium phosphate precipitation) later,
cells were harvested. Total RNA were extracted (40), and 2
g were reverse-transcribed and analyzed (18). Real time
RT-PCRs were performed (18), using sequence-specific
primers (Table 1) (Eurogentec, Angers, France) defined with
the “Primer Express” software (Applied Biosystems, Courtabœuf, France). Analysis of relative gene expression was
done by using the 2⫺⌬Ct method (41).
Nuclear Extracts and Gel Retardation Assays—Nuclear
extracts were prepared using a mini-preparation procedure
(42), and gel retardation assays were performed with the
oligonucleotides shown in Table 2 or in Fig. 5A. The probes
were end-labeled with [␥-32P]dATP (PerkinElmer Life Sciences) using T4 polynucleotide kinase (Promega, Charbonnières, France). FF, ANF, and SF nuclear extracts (5 or 7.5
g) were incubated for 10 min at room temperature with the
probe (5 fmol) in 20 l of a specific binding buffer (43) and in
the presence of 1 g of poly(dI-dC)䡠poly(dI-dC) (Amersham
Biosciences, Orsay, France), used as a DNA nonspecific competitor. For antibody interference reactions, nuclear extracts
were incubated with specific antibodies directed against
c-Krox (antibody developed in collaboration between our
laboratory and Novotec (Lyon, France)), Sp1, Sp3, and CBFb
(Tebu-Bio SA, Le Perray en Yvelines, France) for 10 min at
room temperature and then 10 min at 4 °C. Finally, the probe
was added, and a 10-min incubation at room temperature
was performed. Samples were then fractionated by electrophoresis for 1.5 h at 150 V on a 5% polyacrylamide gel (acrylamide/bisacrylamide at 30:1) in 0.5⫻ TBE (45 mM Tris
borate, 1 mM Na2EDTA) and visualized by autoradiography.
Western Blot Analysis—Fibroblasts were seeded in 55-cm2
wells and at 90% confluency, transiently transfected by the
calcium phosphate precipitation method in the presence of
an expression vector containing or not the hc-Krox cDNA.
17 h after transfection, the medium was replaced by fresh
medium and 24 h later, cells were harvested, and cellular
extracts were prepared as described previously (18). The cellular proteins were fractionated on an 8% polyacrylamide gel
VOLUME 282 • NUMBER 44 • NOVEMBER 2, 2007

Downloaded from http://www.jbc.org/ at Thomas Jefferson University on February 16, 2017

spanning the collagen promoter sequence from ⫺84 to ⫺55
was synthesized containing either G to T mutations at positions
⫺61 and ⫺62 or C to A mutations at positions ⫺73 and ⫺74.
PCR was performed with a single oligonucleotide primer and
the ⫺804hCOL-LUC template for 18 cycles using Pfu Turbo
polymerase (Stratagene) as directed by the manufacturer. The
PCR product was digested with DpnI restriction endonuclease
to eliminate the input template, followed by transformation of
Escherichia coli. Plasmid DNA extracted from bacterial colonies was sequenced using the pGL2 primer (Promega) to confirm the presence of the desired mutations. This gave rise to the
⫺804mut⫺73/⫺74 and ⫺804mut⫺61/⫺62 constructs. The
⫺112 mutant constructs were created by using the ⫺804
mutant constructs as PCR templates with an upstream 18-mer
beginning at ⫺112, and the pGL2 as downstream primer. All
plasmids were sequenced prior to transfection to confirm the
presence of the correct mutations and the promoter length.
Transient Transfections with COL1A1 Constructs—Fibroblasts were passaged after reaching confluency and then distributed in Eppendorf tubes (1 ⫻ 106 cells per 1.5-ml tube).
Cells were centrifuged for 10 min at 200 ⫻ g and transfected
using the Nucleofector apparatus and an NHDF kit (AMAXA,
Köln, Germany), according to the manufacturer’s instructions.
For each sample, 2 g of pSV40/␤-gal expression vector, 2 g of
reporter plasmids, and 1 g of hc-Krox expression vector were
used. After transfection, cells were seeded in 9.6-cm2 wells and
incubated 12 h at 37 °C. The medium was then replaced, and
cells were harvested 6 h later to determine luciferase and ␤-galactosidase activities, as well as the protein amount (38).
The other human COL1A1 plasmid constructs were
described previously (39). pK1A4 Luc and pK1A4mut Luc plasmids were described previously (14).
siRNA Experiments—The following siRNA sequences have
been designed by Qiagen (Courtaboeuf, France): hc-Krox
siRNA forward, r(UCGCUGCUUGCAUGGAGAU)dTdT, and
reverse, r(AUCUCCAUGCAAGCAGCGA)dTdG; control
siRNA forward, r(UUCUCCGAACGUGUCACGU)dTdT, and
reverse, r(UUCUCCGAACGUGUCACGU)dTdT.
FF, ANF, and SF were transfected as described earlier, with
the following modifications. For each sample of 1 ⫻ 106 cells, 1
or 1.5 g of hc-Krox siRNA or control siRNA were added to the
transfection mixture. 12 h after transfection, the medium was
replaced with fresh medium, and 6 h later, cells were harvested
to measure the transcriptional activity or to extract total RNAs.
RNA Extraction and Real Time RT-PCR Analysis—Fibroblasts were seeded in 9.6- or 55-cm2 wells and transiently
transfected by the AMAXA Nucleofector apparatus or the
calcium phosphate precipitation method, respectively, in the
presence of the hc-Krox expression vector (pSG5/hc-Krox)
and/or the corresponding insertless plasmid (pSG5). 12 h

hc-Krox Role in Human Dermal Fibroblasts
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dry milk. Membranes were then
rinsed with TBST and incubated
with secondary antibodies (horseradish peroxidase-conjugated goat
anti-rabbit or anti-mouse antibody) (Tebu-Bio). Type I collagen
and ␤-actin protein bands were
revealed using a Western blot
detection kit (WestPico kit,
Pierce) and quantified with Adobe
Photoshop 7.0.
Immunoprecipitation Assays—10
l of antibody raised against c-Krox
were incubated with 40 l of antirabbit IgG conjugated to agarose
beads (Sigma) in cold 1⫻ phosphate-buffered saline for 2 h at 4 °C.
The samples were then centrifuged
for 15 s at 1200 rpm at 4 °C. The
supernatants were discarded, and
the pellets were rinsed twice with
RIPA buffer (1% IGEPAL CA-630,
1% (w/v) sodium deoxycholate
monohydrate, 0.1% SDS, 0.15 M
NaCl, 40 g/ml aprotinin). Cellular
extracts (corresponding to 2–3 ⫻
106 FF) were added to the substrates, incubated for 2 h at 4 °C, and
centrifuged for 15 s at 1200 rpm.
Supernatants were removed, and
pellets were rinsed four times with
an IP buffer (0.05 M Tris-HCl, pH
7.4, 0.1% Triton X-100, 0.15 M NaCl)
and once with cold phosphate-buffered saline. Then 20 l of 2⫻ sample buffer were added to each
immunoprecipitation reaction, and
samples were denatured at 95 °C for
FIGURE 1. hc-Krox increases type I collagen synthesis and COL1A1 and COL1A2 mRNA steady-state levels
in FF. A, FF were transiently transfected by the calcium phosphate co-precipitation method with 1, 5, and 15 g 5 min and submitted to Western
of pSG5/hc-Krox expression vector. For each amount of hc-Krox transfected, the insertless pSG5 vector was blot assays as described above. Priused as a complement to 15 g, to transfect each sample with the same amount of DNA. 15 h later, the cell mary antibodies against Sp1 (rabbit
culture medium was changed, and a bacterial collagenase assay was realized as described under “Experimental
Procedures.” The values, normalized to total protein amount, are expressed as counts/min/g of protein and anti-human Sp1, 1:300 dilution in
represent the means ⫾ S.D. of triplicate dishes. B, FF were transfected as in A, with a total amount of DNA equal TBST, 2% nonfat milk) and Sp3
to 20 g; total proteins were extracted and used in Western blotting experiments as described under “Exper(rabbit anti-human Sp3, 1:300 diluimental Procedures” to detect type I procollagen and ␤-actin using specific antibodies. The histograms represent the relative expression of type I collagen versus ␤-actin, estimated after densitometric analysis of the tion in TBST, 2% nonfat milk) were
electrophoregram. C, FF were transiently transfected using the AMAXA Nucleofector with 0.1 or 0.5 g of pSG5 purchased from Tebu-Bio. c-Krox
containing or not the hc-Krox cDNA. 18 h after transfection, total RNAs were extracted, and 1 g was reversetranscribed into cDNA. 2 l of cDNAs were diluted 100 times and used in real time PCR to amplify COL1A1 (panel antibody (rabbit anti-mouse c-Krox)
i), COL1A2 (panel ii), hc-Krox (panel iii), and 18 S cDNAs, with specific forward and reverse primers. COL1A1, was used at a dilution of 1:250 in
COL1A2, and hc-Krox mRNAs relative expression was normalized to 18 S rRNA according to 2⫺⌬Ct method (A.U., TBST, 5% nonfat milk.
arbitrary units).
Glutaraldehyde Cross-linking Experiments—10 g of nuclear extracts
(acrylamide/bisacrylamide at 30:1) and electrotransferred were incubated in the presence of 2 l of 0.1% glutaraldehyde or
on a polyvinylidene difluoride membrane (PerkinElmer Life not, in a protein binding buffer (43) for 10 min at room temperSciences). After blocking with TBST (TBS, 0.1% Tween 20) ature. Then 5 l of 5⫻ sample buffer were added, samples were
containing 10% nonfat dry milk, membranes were incubated denaturated for 5 min at 95 °C and subjected to Western blot
with primary antibodies (rabbit anti-human type I collagen, assays as described previously.
dilution 1:1500 (Novotec, Lyon, France), or mouse anti-huChromatin Immunoprecipitation Assay—Chromatin immuman ␤-actin, dilution 1:500 (Tebu-Bio)) in TBST, 2% nonfat noprecipitation assays were performed by using a commercially
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ing amounts of an expression vector
containing the hc-Krox cDNA, and
the collagen neosynthesis was determined after tritiated proline
labeling. We found that hc-Krox
increased the amount of newly synthesized collagen, which includes
type I isotype as the major form in
the dermis (⬃80% of the total collagen) (Fig. 1A). Western blotting
confirmed that this stimulating
effect did affect type I collagen synthesis, indicating that hc-Krox was
acting as an activator on this protein
production (Fig. 1B).
We then asked whether hc-Krox
was exerting the same effect at the
transcriptional level. To this end,
hc-Krox was overexpressed in FF,
and real time RT-PCR analysis was
performed on total RNA extracts.
hc-Krox always increased moderately COL1A1 mRNA steady-state
levels (Fig. 1C, panel i), whereas it
up-regulated more importantly
COL1A2 (Fig. 1C, panel ii) and
COL3A1 (data not shown) mRNA
FIGURE 2. hc-Krox increases type I collagen protein synthesis, and COL1A1 and COL1A2 mRNAs steady- steady-state levels. Effective forced
state levels in ANF. A, ANF were transfected as in Fig. 1A with a total amount of DNA equal to 10 g. 15 h later,
the culture medium was changed, and a bacterial collagenase assay was realized, as described under “Exper- expression of hc-Krox was verified
imental Procedures.” The values, normalized to total protein amount, are expressed as counts/min/g of in FF by measuring the steady-state
protein and represent the mean ⫾ S.D. of triplicate dishes. B, ANF were transfected as in A, with a total amount
of DNA of 20 g, and total proteins were extracted and used in Western blotting experiments as described levels of its mRNA (Fig. 1C, panel
under “Experimental Procedures” to detect type I procollagen and ␤-actin using specific antibodies. Quantifi- iii). Similar experiments were percation of type I collagen expression was performed as described in Fig. 1. C, ANF were transiently transfected by formed on ANF to determine
the AMAXA Nucleofector with 1 g of pSG5 containing or not the hc-Krox cDNA. 18 h after transfection, total
RNAs were extracted, and 1 g was reverse-transcribed into cDNA. 2 l of cDNAs were diluted 100 times and whether hc-Krox regulates type I
used in real time PCR to amplify COL1A1 (panel i), COL1A2 (panel ii), hc-Krox (panel iii), and 18 S cDNAs. COL1A1, collagen expression in this type of
COL1A2, and hc-Krox mRNAs relative expression was normalized to 18 S rRNA according to 2⫺⌬Ct method (A.U.,
dermal fibroblasts in the same way,
arbitrary units).
because contradictory data have
been published.
When increased amounts of hc-Krox were overexpressed
available chromatin immunoprecipitation kit (Active Motif).
Briefly, fibroblasts (10 150-cm2 flasks) were cross-linked, in ANF, collagen neosynthesis was also up-regulated, in a
scraped, and lysed according to the manufacturer’s instruc- dose-independent manner (Fig. 2A). This activation of total
tions. The DNA was then sheared using enzymatic digestion, collagenous protein neosynthesis reflects increased type I
and specific protein-DNA complexes were immunoprecipi- collagen expression, as demonstrated in Western blot analtated using either anti-hc-Krox, anti-Sp1, or anti-Sp3 anti- ysis using a specific anti-type I collagen antibody (Fig. 2B).
bodies. Following overnight immunoprecipitation, cross- However, the increase in type I collagen synthesis appeared
linking was reversed, and the proteins were removed after relatively weak, as compared with the effect on total collagen
treatment with proteinase K, and the DNA was purified and neosynthesis. This could be explained by the fact that Westused as a template in PCR assay. The primers used for the ern blot analysis revealed the total collagen produced by the
amplification of the COL1A1 promoter were as follows: for- cells and not only the newly synthesized fraction. Conseward, 5⬘-CAGAGCTGCGAAGAGGGGA-3⬘, and reverse, quently, hc-Krox effect on the neosynthesized fraction could
5⬘-AGACTCTTTGTGGCTGGGGAG-3⬘. The amplicon corre- be underevaluated.
hc-Krox-induced activation of collagen synthesis was
sponds to a 300-bp fragment that covers the core COL1A1 gene
accompanied with increased COL1A1, COL1A2 (Fig. 2C, panels
promoter (⫺200/⫹100 bp).
i and ii), and COL3A1 (data not shown) mRNA steady-state
RESULTS
levels. Fig. 2C, panel iii, shows that hc-Krox is effectively overhc-Krox Increases Type I Collagen Expression in FF, ANF, and expressed in ANF after transient transfection.
In this study, we show for the first time that hc-Krox is an
SF—We first studied the effect of hc-Krox on total collagen
synthesis in FF. Cells were transiently transfected with increas- activator of type I collagen expression in normal FF and ANF.
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siently transfected with plasmid
constructs covering different regions of human COL1A1 promoter,
in the presence of an expression
vector containing or not the
hc-Krox cDNA. Our data showed
that hc-Krox regulates human
COL1A1 gene in a similar fashion in
both FF and ANF, because in both
cases this transcription factor
up-regulated transcriptional activity of all constructs tested, except
for the shortest one containing only
61 bp of COL1A1 promoter. Therefore, hc-Krox effect is mediated by a
sequence located between ⫺112
and ⫺61 bp (Fig. 4A, panels i and ii).
Because hc-Krox was earlier
reported as an inhibitor of human
COL1A1 gene expression (16, 17), it
was important to demonstrate that
the activating effect observed in
our study was specifically due to
hc-Krox. Therefore, FF and ANF
were transfected with constructs
FIGURE 3. hc-Krox increases type I collagen neosynthesis as well as COL1A1 and COL1A2 mRNAs steady- containing four copies of the
state levels in SF. A, SF were transiently transfected by the calcium phosphate co-precipitation method with c-Krox consensus binding site
10 g of pSG5 containing or not the hc-Krox cDNA. 15 h later, the cell culture medium was changed, and a
bacterial collagenase assay was carried out, as described under “Experimental Procedures.” The values, nor- cloned upstream of the 86 bp of
malized to total protein amount, are expressed as counts/min/g of protein and represent the mean ⫾ S.D. of the mouse Col1a1 short promoter,
triplicate dishes. B, SF were transiently transfected by the calcium phosphate co-precipitation procedure with
1 and 5 g of pSG5/hc-Krox. For each amount of hc-Krox transfected, the insertless pSG5 vector was used as a containing only the TATA box as a
complement to 5 g, to transfect each sample with the same amount of DNA. 15 h after transfection, total RNAs cis-acting element, which was
were extracted, and 1 g was reverse-transcribed into cDNA. 2 l of cDNAs were diluted (1:100) and used in real associated with the luciferase
time PCR to amplify COL1A1 (panel i), COL1A2 (panel ii), hc-Krox (panel iii), and 18 S cDNAs. COL1A1, COL1A2, and
hc-Krox mRNAs relative expression was normalized to 18 S rRNA applying the 2⫺⌬Ct method (A.U., arbitrary reporter gene. hc-Krox specifically
units).
increased the transcription of the
pK1A4Luc construct containing
These observations strongly suggest that hc-Krox could be also four copies of the wild-type c-Krox DNA-binding site,
implicated in several fibrotic situations, such as scleroderma, whereas it did not exert any effect on pK1A4mut Luc transcription in which the four copies of the c-Krox-binding site
where type I collagen expression is increased.
To elucidate this issue, hc-Krox was overexpressed in adult were mutated (Fig. 4B, panels i and ii). Similar data were
SF, and collagen neosynthesis was quantified. As expected, obtained for both FF and ANF and therefore confirm that
basal collagen neosynthesis of SF was greater, compared with hc-Krox is actually a transactivator. Moreover, pK1A4Luc
ANF (⬃300%) (Fig. 3A compared with Fig. 2A). Fig. 3A shows basal transcriptional activity was higher compared with
that hc-Krox up-regulates collagen neosynthesis, and probably pK1A4mut Luc, which means that the endogenous hc-Krox
itself acts as an activator (data not shown).
type I collagen neosynthesis.
To determine whether the regulatory mechanisms of type I
To understand if this activating effect is due to a transcriptional regulation, SF were transiently transfected with collagen expression are the same in SF compared with normal
increasing amounts of hc-Krox expression vector, and fibroblasts, the transcriptional function of hc-Krox was deterCOL1A1 and COL1A2 mRNA were quantified. Overexpres- mined, as done in FF and ANF. As shown in Fig. 4C, forced
sion of hc-Krox increased mRNA steady-state levels of both hc-Krox expression increased transcription of COL1A1
genes (Fig. 3B, panels i and ii), as well as those of COL3A1 through the ⫺112/⫺61 bp indicating that transcriptional reg(data not shown). hc-Krox was clearly overexpressed in our ulatory mechanisms are similar in ANF and SF.
hc-Krox, Sp1, and CBF Interact Specifically with a Human
experimental system (Fig. 3B, panel iii). These results indicate that hc-Krox is an activator of type I and III collagens COL1A1 Promoter Sequence Located between ⫺112 and ⫺61
bp—Subsequently to the previous data, nucleotide analysis of
under fibrotic conditions.
hc-Krox Up-regulates Human COL1A1 Gene Transcriptional the ⫺112/⫺61-bp sequence revealed the presence of one
Activity in FF, ANF, and SF by a Region Located between ⫺112 inverted CCAAT box described previously (⫺101/⫺97 bp
and ⫺61 bp—To investigate the potential hc-Krox effect on (12)), two GC-rich sequences (⫺93/⫺84 bp, 5⬘ GC-rich box;
human COL1A1 gene transcription, FF and ANF were tran- ⫺80/⫺71 bp, 3⬘ GC-rich box) and one putative hc-Krox bind-
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migrating complex is also provided
by antibody interference experiments (Fig. 6B).
Regarding the faster migrating
complex, it most likely corresponds
to hc-Krox, as demonstrated in Fig.
6A, in which a c-Krox antibody was
used in EMSA experiments. Moreover, this complex has the same
migration profile as hc-Krox complexed to an A␣1(I)wt oligonucleotide (Table 2 and Fig. 6C), which is
known to bind specifically c-Krox
and was used to clone mc-Krox
(mouse c-Krox) (14 and data not
shown). As we demonstrated previously, hc-Krox migrates as a doublet, the higher migrating complex
corresponding to hc-Krox monomer and the slower migrating band
to hc-Krox homodimer (14, 15).
In parallel, we analyzed by EMSA
the direct binding of the transcription factors to wild-type and
mutated probes with nuclear
extracts from FF and ANF. Fig. 5B
shows that the binding of hc-Krox,
Sp1, and CBF was not modulated
when the 5⬘ GC-rich sequence was
mutated. By contrast, the binding
activity of these transcription factors was decreased when the 3⬘ GC
box was mutated, indicating that
this region presents more affinity
for these trans factors, compared
with the 5⬘ GC box. A significant
decrease in the binding of hc-Krox,
FIGURE 4. hc-Krox-induced activation of human COL1A1 gene expression, in FF, ANF, and SF is mediated Sp1, and CBF was observed when
by a promoter region located between ⴚ112 bp and ⴚ61 bp. A, FF (panel i) and ANF (panel ii) were tran- the two GC boxes (⫺112/⫺61mut4),
siently cotransfected, by the AMAXA Nucleofector method, with 2 g of different COL1A1 (A), pK1A4 Luc or or only the hc-Krox-binding site
pK1A4 mut Luc (B) reporter plasmids together with 1 g of the pSV40/␤-gal expression vector and 1 g of pSG5
expression vector containing or not (control) the hc-Krox cDNA. 12 h after transfection, the medium was (⫺112/⫺61mut61–62), or only the
changed. 6 h later, the samples were harvested, and protein content, luciferase, and ␤-galactosidase activities CCAAT box (⫺112/⫺61mut3), or
were assayed. Each series of transfections was performed in triplicate. Transcriptional activity of each construct
was expressed as relative luciferase activity (RLU), after correction for both protein amount and transfection when both the GC-rich sequences
efficiency, and expressed as % versus the respective control transfected with the insertless expression vector and CCAAT box were mutated
pSG5. Values represent the mean ⫾ S.D. of three independent samples of a representative experiment. ND, not (⫺112/⫺61mut) (Fig. 5B).
determined. C, SF were transiently cotransfected and treated as described in A and B with the indicated
Overall, from this EMSA analysis,
reporter constructs. Treatment of the samples and expression of the results are the same as in A.
it can be concluded that hc-Krox
and Sp1 bind to the 5⬘ and 3⬘ GC
ing site (⫺67/⫺61 bp) (Fig. 5A), which could bind zinc finger boxes and the ⫺67/⫺61 c-Krox sequence. hc-Krox is the factor
transcription factors such as Sp1, Sp3, and hc-Krox.
that binds with an extremely strong affinity to the ⫺112/
To further investigate the interactions between hc-Krox and ⫺61-bp promoter, compared with Sp1 and CBF. hc-Krox and
DNA in fibroblastic cells, EMSA experiments were performed. Sp1 interact with the three sequences with a decreasing affinity
Fig. 5B (and also supplemental Fig. S1) shows that incubation of order as follows: ⫺67/⫺61 hc-Krox ⬎ 3⬘ GC box ⬎ 5⬘ GC box.
the ⫺112/⫺61wt probe (Fig. 5A and Table 2), with nuclear Moreover, the interaction of CBF with the CCAAT box is
proteins extracted from FF, produced three major complexes strictly dependent on the presence of functional 5⬘ and 3⬘ GC
(1st lane). The slowest migrating correspond to complexes boxes as well as the ⫺67/⫺61 hc-Krox DNA-binding site. The
between DNA and Sp1 and CBF, according to the literature binding of c-Krox and Sp1 is also dependent on the binding of
(43). Additional proof of the presence of Sp1 in the slowest CBF to the CCAAT box.
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below Sp1 disappears, implying that
CBF can bind efficiently on the
⫺112/⫺61-bp region, and again,
when this antibody was used, the
binding of hc-Krox and Sp1 was
slightly decreased, indicating that
CBF facilitates the binding of the
other two zinc finger transcription
factors.
The absence of super-shift in
these assays may be due to the fact
that hc-Krox, Sp1, and CBF antibodies recognize the DNA binding
domain of these transcription factors, preventing their interaction
with DNA, and therefore the formation of the complexes.
Finally, additional experiments
were performed with nuclear extracts
from ANF. As shown in Fig. 6C, hcKrox bound on the ⫺112/⫺61
sequence of the COL1A1 promoter
with a stronger activity compared
with Sp1 and CBF. Mutation of both
GC boxes and of the CCAAT box prevented almost all of the binding of
these three transcription factors, as
shown previously in Fig. 5B (Fig. 6C,
panels i and ii, two panels on the left
part of the figure). Sp1 interacted with
low affinity with the ⫺112/⫺61
COL1A1 sequence compared with a
GC box, present in the first intron
FIGURE 5. hc-Krox, Sp1, and CBF bind specifically to ⴚ112/ⴚ61 bp COL1A1 sequence. DNA binding was
analyzed by EMSA. A, a schematic representation of the ⫺112/⫺61-bp region of COL1A1 gene, including the enhancer of the human COL2A1
CCAAT box, the 5⬘ and 3⬘ GC boxes, and the putative hc-Krox-binding site. The different mutant probes in the gene, which binds Sp1 and Sp3
⫺112/⫺61-bp sequence used in direct binding EMSA experiments are presented. The mutations are indicated
(sequence called enh1 for “enhancer
in italic and are underlined. B, 5 g of FF or ANF nuclear extracts were incubated in direct binding experiments
with the indicated radiolabeled ⫺112/⫺61 wild-type and mutant probes. Arrows indicate the complexes 1”) (38). CBF bound with stronger
formed between DNA and nuclear proteins.
affinity to the ⫺112/⫺61 COL1A1
sequence, compared with Sp1 (Fig.
Additional EMSA were performed to confirm the identity of 6C, panels i and ii, panel in the right part). These data demonstrate
the transcription factors involved in the formation of the differ- that the ⫺112/⫺61 sequence of COL1A1 gene binds the same
ent complexes (Fig. 6). Nuclear extracts prepared from FF were transcription factors (i.e. hc-Krox, Sp1 and CBF) in FF and ANF.
The Proximal Region of COL1A1 Harbors a Functional
incubated in the presence of the radiolabeled ⫺112/⫺61wt
probe and an hc-Krox antibody. In this case, the hc-Krox-DNA ⫺67/⫺61-bp DNA-binding Site for hc-Krox in Dermal
complex formation was abolished (Fig. 6A), and an identical Fibroblasts—Because hc-Krox transactivates human
pattern was observed when nuclear extracts from ANF and SF COL1A1 gene by binding to a sequence located between
⫺112 and ⫺61 bp, we wanted to validate these results in
were used (data not shown).
When an Sp1 antibody was added to the binding reaction, the terms of transcriptional function. For that purpose, we used
Sp1-DNA complex also disappeared (Fig. 6B, upper complex), the ⫺112/⫺61-bp probe and different mutants as decoy olibut it should be noticed that the binding of hc-Krox and CBF to gonucleotides in transfection experiments. FF were transthe probe was decreased, suggesting that Sp1 binding is essen- fected with the pGL2–112-bp construct in the absence of
decoy oligonucleotide or in the presence of a control decoy
tial for the two other transcription factors.
Addition of an Sp3 antibody (Fig. 6B) or an NF-1 antibody oligonucleotide, or the ⫺112/⫺61wt double-stranded
(data not shown) did not modify the interaction pattern of sequence. We found that the ⫺112/⫺61wt decoy oligonuSp1, CBF, and hc-Krox to the wild-type probe, suggesting cleotide decreased significantly the pGL2–112-bp transcripthat this transcription factor does not interact with the tional activity, confirming that this region contains activat⫺112/⫺61-bp sequence of COL1A1 in FF. On the other hand, ing cis elements, including binding sites for hc-Krox, Sp1,
in the presence of a CBF antibody, the complex migrating just and CBF (supplemental Fig. S2).

hc-Krox Role in Human Dermal Fibroblasts

32008 JOURNAL OF BIOLOGICAL CHEMISTRY

VOLUME 282 • NUMBER 44 • NOVEMBER 2, 2007

Downloaded from http://www.jbc.org/ at Thomas Jefferson University on February 16, 2017

mutations in the 3⬘ GC-rich
sequence (112mut⫺73/⫺74) or in
the hc-Krox-binding site located
between ⫺67/⫺61-bp (112mut⫺61/
⫺62). As shown in Fig. 7, the
112mut⫺73/⫺74 reporter plasmids
in FF, ANF, and SF displayed a
decreased transcriptional activity
compared with the 112wt reporter
construct, indicating that the 3⬘GCrich sequence (⫺71/⫺80-bp site)
binds COL1A1 transactivators (Sp1
and hc-Krox, i.e. Fig. 5B). Mutation
of the ⫺61/⫺67 hc-Krox-binding
site in the ⫺112-bp COL1A1 reporter plasmid further decreased
transcription activity indicating
that most part of the hc-Krox functional activity is essentially mediated by the ⫺67/⫺61-bp sequence.
However, it should be noticed
that the inhibition percentages
in the 112mut⫺73/⫺74 reporter
constructs compared with their
respective wild-type promoter
plasmids are lowered in SF compared with ANF, and this is also
observed between ANF and FF.
Similar conclusions can be deduced concerning the 112mut⫺61/
⫺62 constructs. These data may
suggest that a partial functional
redundancy could take place, and it
is linked to the endogenous levels of
the major COL1A1 transactivators
FIGURE 6. Characterization of the transcription factors that bind to the ⴚ112/ⴚ61 bp COL1A1 sequence.
DNA binding was analyzed by EMSA. A and B, double strand radiolabeled ⫺112/⫺61 wild-type oligonucleotide (i.e. hc-Krox, Sp1, and CBF). In
was incubated with FF nuclear extracts (5 g) in the presence or absence of a c-Krox antibody (5 l), an Sp1 other words, the effect of the mutaantibody (2 l)), an Sp3 antibody (2 l), or a CBFb-antibody (2 l). C, 5 g of ANF nuclear extracts were tions in the 3⬘GC-rich sequence or
incubated with the indicated labeled double-stranded probes. Enh1 probe represents the ⫹2817/⫹2842-bp
sequence of human COL2A1 gene that we previously demonstrated to be highly specific for Sp1/Sp3 (31). This in the ⫺61/⫺67 hc-Krox-binding
probe has been used as a positive control to indicate the migration pattern of Sp1. C, panels i and ii, two site can be partly minimized if the
exposures of the autoradiograms are presented; on the left a short exposure, and on the right a longer time of
endogenous levels of activators are
exposure. Arrows indicate the complexes formed between DNA and nuclear proteins.
higher.
Additionally, the functionality of ⫺67/⫺61-bp hc-Krox
Mutation of both ⫺61 and ⫺62 nucleotides in the ⫺67/⫺61
hc-Krox-binding site was able to prevent the inhibition induced sequence has also been validated in forced hc-Krox expression
by the ⫺112/⫺61wt decoy oligonucleotide, indicating that this experiments in the context of the ⫺804-bp COL1A1 promoter
hc-Krox cis element is absolutely critical for the transactivation in FF, ANF, and SF (data not shown). These data suggest that
potential of this short COL1A1 promoter and for the recruit- the ⫺67/⫺61-bp region is required for the recruitment and full
ment of the other activating transcription factors (supplemen- hc-Krox transactivation potential. All together, these experital Fig. S2). These data suggest that the integrity of ⫺112/ ments demonstrate that hc-Krox activates the transcription of
⫺61-bp promoter region of human COL1A1 gene is crucial for COL1A1 gene essentially by the ⫺67/⫺61-bp region of the
the preservation of its basal transcriptional activity and that gene.
A hc-Krox siRNA Prevents hc-Krox-induced Transactivation
hc-Krox and Sp1, as well as CBF, are playing the main roles in
of COL1A1 Gene and Type I Collagen Neosynthesis in FF, ANF,
this regulatory mechanism.
To examine whether the recognition sites for hc-Krox in and SF—To better characterize the transactivating potential of
the ⫺112/⫺61-bp region were able to bind specifically the hc-Krox in fibroblastic cells, the siRNA strategy was used. RNA
cognate transcription factor in human fibroblasts and to interference designed to silence specifically endogenous
effectively modulate transcriptional activity, transient trans- hc-Krox expression was used in transient transfection experifections were performed with reporter constructs bearing ments performed in the three fibroblast cell types. Cells were
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first transfected only with a control siRNA or with a hc-Krox
siRNA, and total RNA was extracted, to check hc-Krox siRNA
efficiency on hc-Krox expression and to determine the resulting
effect on COL1A1 mRNA steady-state levels and transcription.
Real time RT-PCR analysis revealed a significant decrease of
hc-Krox mRNA steady-state levels in FF, ANF, and SF (⬃50 –
85%), which ascertained the siRNA efficiency (Fig. 8, A, panel i,
B, panel i, and C, panel i). Endogenous hc-Krox silencing was
accompanied by an important down-regulation of COL1A1
mRNA steady-state levels (⬃45– 85%), providing further evidence for the hc-Krox activating role on COL1A1 gene transcription in the three types of fibroblasts (Fig. 8, A, panel ii, B,
panel ii, and C, panel ii). Next, the three types of fibroblasts
were transfected with the plasmid construct pGL2–112 bp,
which includes the COL1A1 gene domain mediating hc-Krox
effect, in the presence of a control or hc-Krox siRNAs. The data
demonstrate that the hc-Krox siRNA inhibits pGL2–112 bp
transcriptional activity in FF, ANF, and SF, suggesting that hcKrox interacts with transactivating cis elements present in the
⫺112/⫹1 bp sequence, through which it induces increased
transcriptional activity of the human COL1A1 gene (Fig. 8, A,
panel iii, B, panel iii, and C, panel iii).
Finally, we determined if the observed effects at the transcriptional level in the hc-Krox knockdown experiments were
also detected at the protein level. For that purpose, FF, ANF,
and SF were transiently transfected with control or hc-Krox
siRNAs, and the collagen neosynthesis was determined. As
shown in Fig. 9, the production of newly synthesized collagens
is decreased by ⬃50 – 65% when an hc-Krox knockdown siRNA
was transfected in the three fibroblastic cell types, confirming
that this transcription factor is an activator of type I collagen
expression. Overall, these data demonstrate that hc-Krox has
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FIGURE 7. hc-Krox-induced activation of human COL1A1 gene expression
in FF, ANF, and SF is mediated by the ⴚ80/ⴚ71- and ⴚ67/ⴚ61-bp
sequences. FF, ANF, and SF were transiently cotransfected, by the AMAXA
nucleofector, with 2 g of different COL1A1 reporter plasmids (pGL2-112 bp
wild-type (wt); pGL2–112 bp mutant (mut ⫺73/⫺74); pGL2–112 bp mutant
(mut ⫺61/⫺62)) together with 1 g of the expression vector pSV40/␤-gal.
12 h after transfection, the medium was changed. 6 h later, the samples were
harvested, and protein content, luciferase, and ␤-galactosidase activities
were assayed. Each series of transfection was performed in triplicate. Transcriptional activity of each construct was expressed as relative luciferase
activity after correction for both protein amount and transfection efficiency.
Values represent the mean ⫾ S.D. of three independent samples of a representative experiment.

the same behavior in FF, ANF, and SF, because the same transcriptional regulatory mechanisms affecting the same target
sequences are involved.
hc-Krox, Sp1, and Sp3 Physically Interact in Primary FF—
Our previous data showed that hc-Krox and Sp1 can bind to the
same COL1A1 promoter region, whose integrity is important
for the maintenance of basal transcriptional activity of the gene.
Knowing that hc-Krox contains a BTB-POZ domain allowing
dimerization and interactions with other transcription factors,
we asked whether hc-Krox could interact physically with Sp1
or/and Sp3 transcription factors. To answer this issue, co-immunoprecipitation experiments were performed with nuclear
extracts prepared from FF, using an antibody directed against
c-Krox. Immunoprecipitated proteins were subjected to Western blotting, and the membranes were incubated with c-Krox,
Sp1, or Sp3 antibodies. Immunoblotting with c-Krox antibody
revealed a band corresponding to a complex of ⬃70 kDa, which
matches the hc-Krox apparent molecular weight (67 kDa) and
indicates that hc-Krox was correctly immunoprecipitated (Fig.
10A, panel i). The other two bands of higher electrophoretic
mobility could correspond to ␤- and ␥-hc-Krox homologues.
Similarly, immunoblottings with Sp3 (Fig. 10A, panel ii) and
Sp1 antibodies (Fig. 10A, panel iii) revealed two bands of 85 and
95 kDa corresponding to Sp3 and Sp1 apparent molecular
masses, respectively. These results indicate that Sp3, as well as
Sp1, can interact physically with hc-Krox in primary FF. Moreover, in these experiments, two bands of lower mobility
appeared after treatment with Sp3 antibody; these bands probably correspond to Sp3 longer isoforms or to Sp family homologues. On the other hand, incubation in the presence of Sp1
antibody produced also two bands migrating less than the
95-kDa band, which could be identified as the Sp1-phosphorylated form and/or Sp family homologues.
To verify c-Krox antibody specificity, especially with
respect to Sp1, a Western blot experiment was performed.
As presented in Fig. 10B, the c-Krox antibody does not crossreact with the human recombinant Sp1 protein, therefore
validating the in vivo interaction of hc-Krox and Sp1 as demonstrated in the immunoprecipitation experiments (Fig.
10A, panels i and iii).
To corroborate the above data, protein cross-linking experiments were also carried out. Nuclear extracts prepared from FF
were incubated, in the presence or absence of glutaraldehyde,
and then submitted to Western blot. After blotting, membranes
were incubated with antibodies against c-Krox, Sp3, and Sp1.
Immunoblotting with c-Krox antibody and without glutaraldehyde treatment produced essentially one band of 70 kDa,
corresponding to c-Krox apparent molecular weight (Fig.
10C, panel i). By contrast, in the presence of glutaraldehyde,
the 70-kDa band disappeared, and several bands of lower
electrophoretic mobility were revealed, suggesting that hcKrox from FF is involved in multimeric protein complexes
(Fig. 10C, panel i).
Similarly, when an Sp3 antibody was used and in the absence
of cross-linker, two bands corresponding to Sp3 isoforms
appeared (Fig. 10C, panels ii and iii), whereas in the presence of
glutaraldehyde, the intensity of both bands decreased, and
complexes of higher apparent molecular weight appeared.
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involved in the regulation of COL1A1 gene activation, and to
validate our in vitro experimental data, chromatin immunopre-

32010 JOURNAL OF BIOLOGICAL CHEMISTRY

This study focuses on molecular mechanisms controlling
human COL1A1 gene transcription in physiopathological conVOLUME 282 • NUMBER 44 • NOVEMBER 2, 2007

Downloaded from http://www.jbc.org/ at Thomas Jefferson University on February 16, 2017

cipitation assay was performed. As
shown in Fig. 11, these three zinc
finger proteins bind to the ⫺200-bp
promoter region of COL1A1 in FF.
These factors could therefore interact and could be recruited on the
same region of COL1A1 gene to
favor optimal transactivation.
The Levels of hc-Krox DNA Binding Activity Are Correlated with
Type I Collagen Expression in
Fibroblasts—In this study, we show
for the first time that hc-Krox is an
activator of type I collagen expression in normal and scleroderma
fibroblasts. We next evaluated
whether the endogenous levels of
hc-Krox binding activity could be
correlated with the amounts of type
I collagen produced by fibroblasts.
Thus, we compared side by side the
endogenous expression of type I
collagen (steady-state mRNA, protein levels, and transcriptional
activity) in FF, ANF, and SF, as well
as the corresponding hc-Krox binding activity on the COL1A1 ⫺112/
⫺61 bp promoter. As shown in Fig.
12A, the hc-Krox binding activity is
higher in SF compared with ANF,
which also present a much more
higher DNA binding activity compared with FF. Collagen neosynthesis evaluated in parallel on the same
cells was shown to be approximately
3- and 4-fold higher in SF compared
FIGURE 8. hc-Krox siRNA inhibits the hc-Krox-induced activation of type I collagen expression in FF, ANF, to ANF and FF, respectively (Fig.
and SF. A–C, FF (A), ANF (B), and SF (C) were transiently transfected by the AMAXA nucleofector with 1 g of a 12B). These observed effects on type
control or hc-Krox siRNA. 12 h after transfection, the cell culture medium was changed, and 6 h later, the samples I collagen expression resulted from
were harvested. 1 g of total RNAs extracted was reverse-transcribed into cDNA. 2 l of cDNA were diluted (1:100)
and used in real time PCR to amplify hc-Krox (A, panel i; B, panel i; and C, panel i), COL1A1 (A, panel ii; B, panel ii; and a transcriptional control because
C, panel ii), and 18 S cDNAs. The relative expression of hc-Krox and COL1A1 mRNAs was normalized to 18 S rRNA the transcription of the pGL2–
according to 2⫺⌬Ct method (A.U., arbitrary units). In parallel, fibroblasts were transiently transfected using the
112-bp COL1A1 construct is higher
AMAXA nucleofector with a control or a hc-Krox siRNA (1 g) together with 2 g of pGL2-112-bp construct and 1 g
of the expression vector pSV40/␤-gal. 12 h after transfection, the medium was replaced. 6 h later, the samples were in SF compared with ANF, and also
harvested, and transcriptional activities have been analyzed as described in Fig. 4.
increased in ANF compared with FF
(Fig. 12C). These transcriptional
These data show that Sp3 can also multimerize in FF. Finally, effects were also confirmed at the level of COL1A1, COL1A2,
incubation of the control sample in the presence of an Sp1 anti- and COL3A1 steady-state mRNA amounts (supplemental Fig. S3).
It can be concluded that hc-Krox activates type I collagen
body revealed one band of ⬃95 kDa, which corresponds to Sp1
apparent molecular weight. Addition of glutaraldehyde mark- expression in dermal fibroblasts, and the DNA binding activity
edly reduced the 95-kDa band intensity and produced a multi- of this transcription factor determines, at least in part, the levels
complex of high molecular weight, showing that Sp1 interacts of the endogenous type I collagen expression. Knowing that
with other proteins in FF. These results show that in FF, hc- increased collagen synthesis is a major event observed in scleroKrox, Sp3, and Sp1 form multimeric protein complexes and derma, we may assume that hc-Krox is one of the transcription
factors involved in the COL1A1 up-regulation.
interact between each other.
hc-Krox, Sp1, and Sp3 Bind to the COL1A1 Promoter in Vivo—
To determine whether hc-Krox, Sp1, and Sp3 are effectively DISCUSSION
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ditions. We particularly investigated the role of hc-Krox
transcription factor in human adult and foreskin (from children) normal fibroblasts and in scleroderma fibroblasts. This
approach should later on facilitate the clarification of events
potentially implicated in the manifestation and/or evolution
of the fibrotic reaction. Our results showed that hc-Krox is
able to activate type I collagen expression, at the protein,
transcriptional, and gene activity levels, in all types of primary fibroblastic cells. The data also demonstrate that this
transcription factor interacts physically with Sp1 and Sp3
and that each of these trans factors binds in vivo on the core
promoter of COL1A1.
NOVEMBER 2, 2007 • VOLUME 282 • NUMBER 44

Our particular interest for hc-Krox function in human skin
fibroblasts comes from the fact that this factor has been
described previously as an inhibitor of type I collagen expression in NIH-3T3 mouse fibroblastic cells (16). These data suggested that hc-Krox could be involved in the fibrotic process
and make it a motivating target to better understand scleroderma. The present results revealed in fact that hc-Krox is a
potent activator of type I collagen expression in normal foreskin
and adult fibroblasts but also in scleroderma cells. The discrepancy between our study and previous results can be due to the
cell type and/or to different experimental procedures used. For
example, the transfection method employed here is the Amaxa
nucleofection, which is, in our hands, the more appropriate
method to obtain high transfection efficiency and proper expression of the reporter gene, especially for high size reporter vectors.
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 9. hc-Krox siRNA inhibits the hc-Krox-induced increase of type I
collagen neosynthesis in FF, ANF, and SF. FF, ANF, and SF were transiently
transfected by the AMAXA nucleofector with 1 g of a control or of hc-Krox
siRNA. 12 h after transfection, the cell culture medium was replaced, and
the cells were incubated in the same fresh medium supplemented with
␤-aminopropionitrile (50 g/ml) and ascorbic acid (50 g/ml) for a further
24-h period. The same medium was then renewed, and [3H]proline (2
Ci/ml) was added. After 24 h, the culture medium was collected and the
labeled collagen was assayed, using the bacterial collagenase method.
The values, normalized to total protein amount, are expressed as counts/
min/g of protein and represent the mean ⫾ S.D. of triplicate dishes.

FIGURE 10. hc-Krox, Sp1, and Sp3 interact physically in FF. A, hc-Krox was
immunoprecipitated (IP) in total cellular extracts prepared from 2.5 ⫻ 106 FF.
Proteins isolated after immunoprecipitation were denatured and separated
by SDS-PAGE. Three samples were transferred to polyvinylidene difluoride
membranes and reacted with polyclonal antibodies against hc-Krox (panel i),
Sp3 (panel ii), and Sp1 (panel iii). Proteins were revealed with a peroxidasecoupled secondary antibody (anti-rabbit IgG) using a West-Pico Western
detection kit. Arrows indicate the molecular weight of proteins recognized by
antibodies, as estimated by prestained marker proteins. B, 1 l of human
recombinant Sp1 protein (Promega) was separated by SDS-PAGE. The samples were then transferred to polyvinylidene difluoride membranes, which
were reacted with polyclonal antibodies directed against hc-Krox (1:100 dilution) and Sp1 (1:300 dilution). Protein was revealed with a peroxidase-coupled secondary antibody (anti-rabbit IgG) using a West-Pico Western detection kit. C, 10 g of FF nuclear extracts were incubated with or without 2 l of
glutaraldehyde 0.1%, during 10 min at room temperature. Proteins were then
denaturated and separated by SDS-PAGE. Samples were transferred to polyvinylidene difluoride membranes and reacted with antibodies against hcKrox (panel i), Sp3 (panels ii and iii), and Sp1 (panel iv). Proteins were revealed
as in A. Arrows indicate the molecular weight of proteins recognized by antibodies, as estimated by prestained marker proteins. Panel iii represents a
shorter film exposure as compared with ii.
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hc-Krox inhibiting effects have been associated to its BTB/
POZ domain. In the case of promyelotic leukemia zinc finger,
the BTB/POZ domain is located at the N-terminal extremity
and interacts with co-repressors, like silencing mediator for
retinoid and thyroid hormone receptors, and nuclear receptor
co-repressor. Co-repressors recruit histone deacetylase 1 that
interacts with the target promoter and inhibits its transcriptional activity, modifying locally the chromatin structure (44).
However, all transcription factors carrying BTB/POZ domains
are not trans-repressors. For example, Drosophila CAGA transcription factor, encoded by Trithorax-like gene, enhances
transcription activity by preventing chromatin condensation.
In this case, the BTB/POZ domain provokes the oligomerization of CAGA factor, and this structure allows direct interaction with many sites of DNA to the detriment of the nucleosome structure in a way that makes the promoter accessible to
transactivators (45).
Moreover, it is not very surprising that hc-Krox behaves as an
activator of collagen in skin fibroblasts because we demonstrated that its mouse homologue, mc-Krox, is an activator of
mouse Col1a1 gene in NIH-3T3 fibroblasts (14). Additionally,
we showed that mc-Krox is highly expressed in skin and that its
expression during development precedes at least 3 days type I collagen expression (14). This element strongly suggests that c-Krox
is a factor that could initiate and enhance type I collagen synthesis.
Even if the mc-Krox cDNA at that time was an incomplete
clone lacking the BTB/POZ domain, we have shown that the
transactivating effects exerted on target gene transcription
were mediated by its C-terminal extremity and the zinc finger
domain (15). This is in agreement with the observations of
Widom et al. (16), who showed that the truncation of hc-Krox
N-terminal domain (but not of BTB/POZ domain alone) leads
to an activation of target genes transcription, thus preventing
the inhibiting effect.
Currently, no identified mechanism characterizing c-Krox
function is known. Nevertheless, an interesting example of
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FIGURE 12. The endogenous hc-Krox DNA binding activity to COL1A1
gene in fibroblasts is correlated with type I collagen synthesis. A, DNA
binding was analyzed by EMSA. 7.5 g of FF or ANF or SF nuclear extracts
were incubated with the radiolabeled ⫺112/⫺61 wild-type probe, in direct
binding experiments. Arrow indicates the complexes formed between DNA
and hc-Krox. B, confluent cultures of FF, ANF, and SF were preincubated for
24 h in Dulbecco’s modified Eagle’s medium ⫹ 10% fetal calf serum supplemented with ␤-aminopropionitrile (50 g/ml) and ascorbic acid (50 g/ml).
The same medium was then renewed, and [3H]Proline (2 Ci/ml) was added.
After 24 h, the cell culture medium was collected, and the labeled collagen
was assayed, using the bacterial collagenase method, as described under
“Experimental Procedures.” The values, normalized to total protein amount,
are expressed as counts/min/g of protein and represent the mean ⫾ S.D. of
triplicate dishes. C, FF, ANF, and SF were transiently transfected using the
AMAXA nucleofector with 2 g of pGL2–112-bp construct and 1 g of the
expression vector pSV40/␤-gal. 12 h after transfection, the medium was
replaced. 6 h later, the samples were harvested, and transcriptional activities
have been analyzed as described in Fig. 4.

transcription factors having a dual activation or repression
domain has been reported for YY1 (“Yin Yang-1”), another
Krüppel-like factor. Thus, YY1 can activate or inhibit target
gene transcription depending on its relative concentration,
of the promoter, and/or of the cellular context (46 – 49). The
mechanism proposed to explain its bifunctional effect is
related to the interaction of the factor with histone acetyltransferases, such as CBP, p300, and PCAF (CBP/p300 associated factor) and histone deacetylases 1-, -2, and -3 (50, 51).
These findings, together with the capacity of YY1 to interact
with Sp1, GATA-1, and c-Myc (52, 53) suggest an hypothesis
for hc-Krox function.
This hypothesis could be supported by the fact that c-Krox
can homo- or heterodimerize through its BTB/POZ or C-terminal domains (15, 17). Although the proteins interacting with
this factor are not yet all identified, it seems very plausible that
the transactivating effects of hc-Krox could depend on the spatial configuration of the protein, on the promoter sequences
surrounding c-Krox-binding sites and, on the context of the
transcriptional partner.
VOLUME 282 • NUMBER 44 • NOVEMBER 2, 2007
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FIGURE 11. hc-Krox, Sp1, and Sp3 bind in vivo to the COL1A1 promoter.
Ten flasks of FF cultures were fixed, digested, and immunoprecipitated overnight by hc-Krox, Sp1, and Sp3 antibodies. These steps were followed by PCR
amplification with primers flanking the ⫺112/⫺61 sequence of the COL1A1
promoter. As positive control (Input), the same primers were used on the
genomic DNA. Samples were also immunoprecipitated with anti-RNA polymerase II used as positive control (C⫹) and with a nonspecific immunoglobulin used as a negative control (C⫺).
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that the ⫺198/⫹1-bp proximal promoter, and particularly the
⫺112/⫺61-bp sequence, plays a critical role in the regulation of
human COL1A1 gene in human skin fibroblasts. Besides, it is
noteworthy that the binding of each factor is dependent of the
binding of the others.
In this sense, transient transfections were performed with
reporter constructs bearing mutations in the 3⬘ GC-rich
sequence or in the hc-Krox-binding site located between ⫺67/
⫺61 bp. The data revealed that the extent of inhibition in the
mutated reporter constructs compared with their respective
wild-type promoter plasmids is lower in SF compared with
ANF, and this effect is even more pronounced when compared
with FF. We therefore hypothesize that a partial functional
redundancy could be effective, and this is probably because of
the fact that endogenous levels of the major COL1A1 transactivators such as hc-Krox, Sp1, and CBF display a greater DNA
binding activity in SF compared with the normal fibroblasts.
This means that the effect of the mutations in the 3⬘ GC-rich
sequence or in the ⫺61/⫺67 bp hc-Krox-binding site can be
partly counteracted if the endogenous levels of activators are
higher.
Additionally, our results are in agreement with those
obtained by Hitraya et al. (56) who reported that the maximal transcriptional activity of COL1A1 is located within the
⫺129- and ⫺84-bp region. This region includes two tandem
NF1/Sp1 elements (⫺129/⫺107-bp and ⫺104/⫺78-bp) and
the CCAAT-box, and the cognate transcription factors display a higher binding activity in nuclear extracts from SSc
fibroblasts (12, 56). We demonstrate here that hc-Krox also
appears to have a pivotal role in the activated expression of
COL1A1 in SSc fibroblasts, because its DNA binding activity
is increased in SF nuclear extracts in comparison with the
nuclear extracts from normal cells (ANF and FF). Moreover,
our observations suggest that hc-Krox is involved in both
basal and increased COL1A1 transcription and that the level
of hc-Krox DNA binding activity is closely correlated with
the type I collagen expression in fibroblasts, as demonstrated
for Sp1 and CBF (12, 56).
To explain that the ⫺112/⫺61-bp sequence binds mainly
hc-Krox in our EMSA, and to a much more lower extent CBF
and Sp1, we propose that our probe covers the oligonucleotidic
sequence between ⫺78 to ⫺61 bp in which we have identified
for the first time a new hc-Krox DNA-binding element (i.e.
⫺67/⫺61 bp), which is responsible for the main part of the
transactivating effect of this factor as demonstrated in
mutagenesis functional assays (Fig. 7). By contrast, other studies have restricted their analysis to the ⫺104/⫺78-bp region
and have not focused on the downstream sequences.
Taken together, these data suggest that, in human skin fibroblasts, the ⫺112/⫺61-bp region may interact with several transcription factors exerting activating effects on human COL1A1
gene transcription, but also promoting interactions with TATA
box and/or other promoter or intron sequences of the gene.
In conclusion, we have characterized the transcriptional
function of hc-Krox on human COL1A1 gene in healthy foreskin fibroblasts and correlated these findings with data
obtained in adult normal and scleroderma fibroblasts. Given
the relatively tissue-restricted expression of hc-Krox compared
JOURNAL OF BIOLOGICAL CHEMISTRY
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Indeed, previous results showed that hc-Krox inhibits human
COL2A1 and UGDH genes transcriptional activity in differentiated and de-differentiated rabbit articular chondrocytes by binding close to Sp1/3-binding sites (18, 38),6 whereas it activates the
human COL1A1 gene in skin fibroblasts by interacting with Sp1
and Sp3 (this paper). Thus, at the same time hc-Krox seems to be a
pro-arthrotic and a pro-fibrotic factor, suggesting its involvement
in inflammatory or/and immune responses.
It has been shown recently that the full-length mc-Krox plays
a key role in the differentiation of thymocytes in CD4 helper
rather than in CD8 killer T lymphocytes (19, 20). Constitutive
expression of c-Krox in helper-deficient mice led to the differentiation of class I-restricted thymocytes in CD4⫹ cells,
whereas overexpression of a mutant form of this transcription
factor appeared functionally inert (20). Interestingly, during the
first stages of scleroderma disease, an accumulation of CD4⫹
lymphocytes is observed, whereas CD8⫹ population is
decreased. CD4⫹ cells migrate in vascular epithelium and dermis connective tissues and lead to an activation of target cells
and to an increased production of pro-fibrogenic growth factors and cytokines (22, 54). Taken together, these data suggest
that hc-Krox could be one of the first actors involved in the
manifestation of scleroderma, playing a role in the immune
reaction but also in the remodeling of dermis ECM.
This study provides some evidence about this last issue,
because hc-Krox was found to increase COL1A1 transcriptional activity and not only COL1A1, COL1A2, and COL3A1
mRNA steady-state levels but also Sp1 and Sp3 transcription
(data not shown), two other activators of type I collagen genes
(6, 10, 11, 28, data not shown). These three zinc finger factors
interact with the same human COL1A1 promoter region as
demonstrated in chromatin immunoprecipitation experiments, through which they exert their activating effects (this
study and data not shown). Artlett et al. (55) showed that this
region is sufficient to confer maximal transcriptional activity of
the human COL1A1 gene in vitro. From a transcriptional point
of view, nucleotide analysis of the 198-bp sequence revealed
four potential binding sites for hc-Krox (⫺168/⫺141,
⫺93/⫺84, ⫺80/⫺71, and ⫺54/⫺47 bp), all of them overlapping with Sp1/Sp3 potential binding sites. EMSA experiments
showed that hc-Krox can bind with high affinity to ⫺168/
⫺141- and ⫺80/⫺71-bp sequences, whereas its affinity for the
other two sites is very low (data not shown). However, from our
EMSA analysis and transient transfection assays, we have identified a new ⫺67/⫺61-bp sequence binding hc-Krox that
clearly mediates a great part of its activating effect in FF, ANF,
and SF.
Our data also demonstrate that in terms of binding affinity
and amount, hc-Krox is the major transcription factor interacting with the ⫺112/⫺61-bp region, compared with CBF and
Sp1. Moreover, as demonstrated by Cicchillitti et al. (43), we
confirmed that Sp1 and CBF interact with this sequence, and
the latter one binds much more efficiently compared with Sp1.
CBF interacts with the ⫺100/⫺96-bp sequence, enhancing
COL1A1 transcriptional activity, providing further evidence

hc-Krox Role in Human Dermal Fibroblasts
with Sp1 and CBF, all these data make this factor an attractive
candidate for setting up therapeutic strategies against fibrotic
diseases. Additionally, we showed for the first time that hcKrox is able to form macromolecular complexes with other
transcription factors such as Sp1 and Sp3. This element, associated with the fact that all three factors exert their transactivating effects through a COL1A1 198-bp short promoter, will
allow us to develop further analysis of human COL1A1 gene
regulation of expression, taking into account the complexity of
molecular mechanisms controlled by direct or indirect interactions between endogenous nuclear factors under normal and
pathological conditions.
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Figure S1. hc-Krox, Sp1, and CBF bind specifically to -112/-61 bp COL1A1 sequence.
DNA binding was analyzed by EMSA.
Panel A.i – A double-strand radiolabeled -112/-61 wt oligonucleotide was incubated with FF
nuclear extracts (5 µg) (lanes 2-13) or with human recombinant Sp1 protein (Promega,
Charbonnières, France) (lane 14). Competition with molar excesses of cold wild-type and
mutant oligonucleotides were performed (-112/-61wt: lanes 3-4, -112/-61mut: lanes 5-6, 112/-61mut1: lanes 7-9, -112/-61mut2: lanes 10-11, -112/-61mut3: lanes 12-13). Lane 1
represents the probe incubated without nuclear extracts. Panel A.ii represents a magnification
of C1 and C2 complexes corresponding respectively to Sp1 and CBF. Panel B – 5 µg of FF
nuclear extracts were incubated with a double-strand labeled -112/-61 wt oligonucleotide
(lanes 1-6) in the presence of molar excesses of cold wild-type and mutant oligonucleotides (112/-61wt (lanes 2-3), -112/-61mut4 (lanes 4-6)). Arrows indicate the complexes formed
between DNA and nuclear proteins.
Fig. S1Ai shows that incubation of the -112/-61wt probe (Table I) with nuclear proteins
extracted from FF, revealed two major complexes (lane 2). The slowest migrating two bands,
called C1 and C2, are magnified in Fig. S1Aii, and correspond, according to the literature
(43), to complexes between DNA and Sp1 (C1) or CBF (C2). To get more information about
the identity of the C1 complex, the same oligonucleotide was incubated with the human
recombinant Sp1 protein (lane 14) and only one complex, having an identical migration
profile as C1, was detected. These data provide further evidence that C1 corresponds to Sp1.
Another proof of the presence of Sp1 in C1 complex was also provided by antibody
interference experiments (Fig. 6B).
The binding specificity of these two complexes (C1 and C2) was studied in competition
experiments, using wild-type and mutated oligonucleotides presented in Table I and Fig. 5A.
Thus, competition with an unlabeled -112/-61wt oligonucleotide decreased the binding of
both complexes (lanes 3, 4), suggesting the specificity of the interactions observed between
proteins and DNA. When the -112/-61mut was used as a cold competitor, in which both GCrich sequences and the CCAAT box were mutated, a decrease of the binding activity of Sp1,
CBF and hc-Krox to the probe was found (lanes 5, 6). This finding indicates that another cis
element is able to bind or recruit the three transcription factors in the -112/-61-bp region. The
data provide further evidence that mutation of the three boxes present on -112/-61 bp
COL1A1 sequence is not sufficient to prevent the binding of proteins interacting with the wild
type sequence. Additionally, when the 5’ GC-rich box was mutated (-112/-61mut1) and used
as a competitor (lanes 7-9), the formation of Sp1/CBF-DNA and hc-Krox-DNA complexes
was reduced, demonstrating that the transcription factors are still able to directly interact with
the inverted CCAAT box and the 3’ GC-rich box which are not mutated, as well as with other
domains of the -112/-61 bp sequence located in 3’.
Mutation only in the 3’ GC-rich box (-112/-61mut2) competed efficiently the binding of
Sp1, CBF and hc-Krox to the probe (lanes 10, 11). This suggests that an interaction of Sp1
and hc-Krox with the 5’ GC-rich and with the putative hc-Krox cis element (-67/-61) is
possible. When a cold competitor mutated only in the CCAAT box was used, it significantly
reduced the binding of the three transcription factors (lanes 12, 13). The observation of lanes
12, and 13 reveals a significant decrease of the C2 complex (which corresponds to CBF), that
normally should not be altered, and strongly suggests that CBF needs to interact with factors
binding to the GC-rich boxes in order to bind efficiently on COL1A1 promoter. Finally,
competition with a -112/-61mut4 oligonucleotide, in which both GC-rich sequences were
mutated, was able to slightly compete away the binding of hc-Krox, Sp1 and CBF to the wildtype probe, confirming that these transcription factors can be recruited probably through the 67/-61 hc-Krox site (Fig. S1B).

Figure S2. Decoy oligonucleotides corresponding to -112/-61 bp promoter region of
COL1A1 gene are able to reverse hc-Krox transactivating effect.
Panels A, B and C - FF were transiently transfected by the AMAXA nucleofector with 2 µg of
pGL2-112 bp construct and 1 µg of the expression vector pSV40/β-gal. 30 µg of different
oligonucleotides corresponding to the wild type -112/-61 bp sequence or mutant derivatives
(indicated on the Fig.) were added in the culture medium immediately after transfection. 12
hrs after transfection, the medium was changed and supplemented with the same decoy
oligonucleotide (30 µg). 6 hrs later, cells were harvested and relative transcriptional activities
have been analyzed.
Having shown that hc-Krox can transactivate human COL1A1 gene by binding to a
sequence located between -112 and -61 bp, we tried to validate these results in terms of
transcriptional function. We used the -112/-61 bp probe and different mutants as decoy
oligonucleotides in transfection experiments. FF were transfected with the pGL2-112 bp
construct in the absence of decoy oligonucleotide or in the presence of a control decoy
oligonucleotide (a sequence of the human COL2A1 intronic enhancer binding specifically
SOX9 transcription factor), or the -112/-61wt double-stranded sequence. We found that the 112/-61wt decoy oligonucleotide decreased significantly the pGL2-112 bp transcriptional
activity, confirming that this region contains activating cis elements, including binding sites
for hc-Krox, Sp1, and CBF (Fig. S2A). To determine the possible involvement of the 5’ and
3’ GC-rich sequences and the CCAAT box in the transcription activity of the -112 bp
COL1A1 promoter, several mutants were used. As shown in Fig. S2A, transfection of a decoy
oligonucleotide presenting a mutation in both 5’ and 3’ GC boxes, together with a mutation in
the CCAAT box, allowed to maintain almost all of the basal transcription activity of the -112bp COL1A1 promoter, demonstrating that hc-Krox and Sp1 bind to the two GC boxes and
CBF to the CCAAT sequence, and that all are transactivators.
In Fig. S2B, a hc-Krox consensus oligonucleotide (DAα1(I)wt), used as a decoy, inhibited
the transcription of the pGL2-112 bp construct, confirming again that hc-Krox is an activator
of COL1A1 transcription. In this set of experiments, -112/-61 bp mutants were also used as
competitors. D-112/-61mut1 (for decoy -112/-61 bp mut1, mutation in the 5’ GC-rich
sequence), which competes for CBF and partially for Sp1 and hc-Krox binding, slightly
reduced the 112 bp promoter activity, suggesting that Sp1 and hc-Krox still bind respectively
on the 5’-GC-rich and the hc-Krox regions, and are sufficient to maintain almost all the basal
transcriptional activity of the promoter. However, D-112/-61mut2 (mutation only in the 3’
GC-rich sequence) and D-112/-61mut3 (mutation in the CCAAT box) induced a greater
decrease of the 112 bp promoter activity. These data demonstrate that the integrity of the 5’
and 3’ GC-rich sequence, but also the -67/-61 cis element and the CCAAT box are important
for the maintenance of the basal activity of the promoter. Moreover these results are in
agreement with our EMSA results which show that hc-Krox, Sp1 and CBF bind on the -112/61 bp sequence in an interdependent way, and prove that all of them are activators of the
COL1A1 gene transcription. Moreover, the use of -112/-61mut4 decoy, which allowed a very
weak Sp1 and hc-Krox binding to the promoter, abrogating CBF fixation and inducing a
down-regulation of promoter activity comes as a further support to our previous findings
according to which hc-Krox, Sp1 and CBF binding on -112/-61 bp sequence is
interdependent.
Mutation of both -61 and -62 nucleotides in the -67/-61 hc-Krox binding site was able to
prevent the inhibition induced by the -112/-61wt decoy oligonucleotide, indicating that this
hc-Krox cis element is absolutely critical for the transactivation potential of this short
COL1A1 promoter and for the recruitment of the other activating transcription factors (Fig.

S2C). The same decoy strategy was also applied to ANF and similar data were obtained when
-112/-61wt, -112/-61mut, and -112/-61mut-61-62 sequences were used as decoy
oligonucleotides (data not shown).
These data suggest that the integrity of -112/-61 bp promoter region of human COL1A1
gene is crucial for the preservation of its basal transcriptional activity and that hc-Krox and
Sp1, as well as CBF, are playing the main roles in this regulatory mechanism.
Figure S3. The hc-Krox endogenous DNA-binding activity to COL1A1 gene in
fibroblasts is correlated with type I collagen synthesis.
Total RNAs were extracted from FF, ANF, and SF cultures. 1 µg of total RNAs was reversetranscribed into cDNA. 2 µl of cDNAs were diluted 100 times and used in real time PCR to
amplify COL1A1 (panel A), COL1A2 (panel B), COL3A1 (panel C) and GAPDH cDNAs,
with specific forward and reverse primers. COL1A1, COL1A2, and COL3A1 mRNAs relative
expression was normalized to GAPDH mRNA according to 2-deltaCT method (A.U. Arbitrary
Units).
The results indicate that SF express higher amounts of COL1A1, COL1A2, and
COL3A1 mRNA compared to ANF. The same conclusion is also true for ANF compared to
FF.
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